吴力军

2017-06-23


1992年至1999年在美国加州卫生部作访问学者;1998年至2001年任美国Zyomyx公司研究科学家;2001年至今任ProMab Biotechnologies Inc. CEO兼技术负责人。

作为单克隆抗体以及免疫治疗相关开发领域专家,领衔开发5000余株肿瘤及相关单克隆抗体细胞株;成功建立鼠源,兔源,以及人源化三大抗体平台技术,在CAR-T免疫治疗领域带领团队筛选出超过40余个潜在肿瘤靶标,并在免疫治疗安全性、特异性、复发性以及标准化生产工艺上具有特殊造诣,并申请美国和国际发明专利10余项。

From 1992 to 1999, John as a visiting scholar worked at the Ministry of Health in California. He established ProMab Biotechnologies Inc. in 2001 as CEO and technology leader.

As a monoclonal antibody and immunotherapy expert, John led to develope more than 5000 monoclonal antibody cell lines and successfully established of mouse, rabbit, and humanized antibody technology platform. His team screened more than 40 potential cancer targets. Because of his special ability in CAR safety, specificity design and standardized production process, He applied about 10 PCT & US inventional patent application in the field of this filed.

上一篇:周伟丽
下一篇:陈雁如
Powered by 飞色网络